Jaguar Animal Health, Inc. (NASDAQ:JAGX) Short Interest Up 68.6% in July

Jaguar Animal Health, Inc. (NASDAQ:JAGX) saw a large growth in short interest in the month of July. As of July 31st, there was short interest totaling 87,153 shares, a growth of 68.6% from the July 15th total of 51,687 shares. Approximately 14.5% of the shares of the company are sold short. Based on an average daily volume of 119,074 shares, the short-interest ratio is presently 0.7 days.

Analyst Ratings Changes

Several brokerages recently weighed in on JAGX. Wall Street Zen raised Jaguar Animal Health from a “sell” rating to a “hold” rating in a report on Saturday, May 23rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Jaguar Animal Health in a research report on Friday, July 17th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Jaguar Animal Health Stock Performance

JAGX stock traded down $0.04 during trading on Monday, hitting $0.88. 120,398 shares of the company traded hands, compared to its average volume of 105,603. The firm has a market capitalization of $527,340.00, a PE ratio of -0.00 and a beta of -0.06. Jaguar Animal Health has a 1 year low of $0.72 and a 1 year high of $85.40. The company has a 50-day moving average of $1.90 and a 200-day moving average of $9.84.

Jaguar Animal Health (NASDAQ:JAGX) last issued its quarterly earnings data on Wednesday, May 20th. The biotechnology company reported ($13.60) EPS for the quarter, beating the consensus estimate of ($149.10) by $135.50. The firm had revenue of $20.27 million for the quarter, compared to the consensus estimate of $4.21 million.

Jaguar Animal Health Company Profile

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.